Alzheimer's Clinical Trials

2 recruiting

Alzheimer's Trials at a Glance

52 actively recruiting trials for alzheimer's are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Miami, Tampa, and Orlando. Lead sponsors running alzheimer's studies include Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Anhui Medical University, and Intra-Cellular Therapies, Inc..

Browse alzheimer's trials by phase

Treatments under study

About Alzheimer's Clinical Trials

Looking for clinical trials for Alzheimer's? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alzheimer's trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alzheimer's clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 52 trials

Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled416 locationsNCT05980949
Recruiting
Phase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled71 locationsNCT07033494
Recruiting
Not Applicable

Remotely-supervised Neuromodulation in PPA

Primary Progressive Aphasia(PPA)Progressive AphasiaProgressive Aphasia in Alzheimer's Disease+3 more
Maya Henry80 enrolled2 locationsNCT07260253
Recruiting

InRAD Observational Study

Mild Cognitive Impairment (MCI)Alzheimer's Disease(AD)Subjective Cognitive Decline (SCD)+1 more
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation50,000 enrolled1 locationNCT07213700
Recruiting
Phase 2Phase 3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled14 locationsNCT07284472
Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Not Applicable

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

Deep Brain StimulationMild Cognitive ImpairmentMild Alzheimer's Disease+1 more
University of California, Los Angeles144 enrolled1 locationNCT05417555
Recruiting
Phase 2

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics210 enrolled3 locationsNCT07459660
Recruiting
Not Applicable

Improving PCP Advance Care Planning for People With ADRD

DementiaAlzheimer DiseaseAging+1 more
University of Pittsburgh120 enrolled1 locationNCT06565169
Recruiting
Phase 2

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Mild, Moderate, or Severe Alzheimer's Disease
Elixiron Immunotherapeutics (Hong Kong) Ltd.15 enrolled2 locationsNCT06745583
Recruiting
Not Applicable

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer Disease, Late Onset+2 more
Massachusetts Institute of Technology60 enrolled1 locationNCT05655195
Recruiting

Speech Pattern Evaluation and Analysis for Knowledge of AD

Wisconsin Alzheimer's Disease Research CenterWisconsin Registry for Alzheimer's Prevention
University of Wisconsin, Madison165 enrolled1 locationNCT06230783
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled26 locationsNCT06887192
Recruiting
Phase 3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
JYAMS PET Research & Development Limited316 enrolled2 locationsNCT07422857
Recruiting
Phase 2

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
Brigham and Women's Hospital16 enrolled1 locationNCT06489548
Recruiting
Not Applicable

Feasibility of Wearables in Dementia Care in Rural Taiwan

Circadian RhythmAlzheimer's DementiaNeuropsychiatric Symptoms Related to Neurodegenerative Disease+2 more
China Medical University Hospital20 enrolled1 locationNCT07249918
Recruiting
Not Applicable

Autophagy-Enhancers to Reduce Sleep Disturbances

Mild Cognitive Impairment Due to Alzheimer's Disease
University Medicine Greifswald76 enrolled1 locationNCT07383311
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833